Result of General Meeting and Change of Name
N4 Pharma PLC has officially changed its name to Thalia Therapeutics plc, effective March 18, 2026, with its ticker symbol on the London Stock Exchange changing from N4P to THAT. This rebranding signifies the company's strategic shift towards becoming a therapeutics-focused biotechnology firm, leveraging its proprietary Nuvec® gene delivery system to advance treatments for cancer and other diseases. Existing share certificates remain valid, and shareholders' holdings are unaffected by the name change.
Select text to share a quote on X · sign in to keep highlights & notes in your THAT notes
N4 Pharma plc (AIM: N4P), the UK biotech developing Nuvec®, its proprietary gene delivery system to enable advanced therapies for cancer and other diseases, is pleased to announce that at the General Meeting of the Company held earlier today, the special resolution to change the Company's name to Thalia Therapeutics plc was duly passed.
The Company further announces that the change of name has now taken effect following registration at Companies House and will become effective on the London Stock Exchange tomorrow, 18 March 2026.
The Company's TIDM will change from N4P to THAT. The Company's LEI (213800OIN8T68PM7HK77), ISIN (GB00BYW8QM32) and SEDOL (BYW8QM3) will remain unchanged.
Shareholders should note that their holdings of ordinary shares in the Company will not be affected by the change of name. Existing share certificates should be retained as they remain valid for all purposes and new share certificates will not be issued.
Pursuant to AIM Rule 26, the proxy votes received in relation to the resolution will be made available on the Company's website, and the Company's website will be updated from tomorrow at https://www.thaliatx.com
Dr David Solomon, Chief Executive Officer of Thalia Therapeutics, commented:
"The change of name to Thalia Therapeutics reflects our strategic evolution into a therapeutics-focused biotechnology company. With a growing RNA therapeutics pipeline and our proprietary Nuvec® delivery platform, we believe the Company is well positioned to advance innovative treatments and deliver long-term value for shareholders."
| N4 Pharma plc Dr Chris Britten, Chairman Luke Cairns, Executive Director Dr David H Solomon, CEO | Via Thalia Investor Hub https://investors.thaliatx.com/link/PbL5Ge |
| SP Angel Corporate Finance LLP Nominated Adviser and Joint Broker Matthew Johnson/Jen Clarke (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking) | Tel: +44 (0)20 3470 0470 |
| Turner Pope Investments (TPI) Limited Joint Broker Andy Thacker Guy McDougall | Tel: +44 (0)20 3657 0050 |
| Northstar Communications Limited Investor Relations Sarah Hollins | Tel: +44 (0)20 7183 2463 |
Cleaned text: letterheads, contacts and legal notices removed. View the original announcement ↗ · Company filings. Not investment advice.